Zentalis shareholders elect two Class III directors, ratify auditor, approve say-on-pay at 2026 annual meeting

Zentalis Pharmaceuticals, Inc.

David Johnson and Jan Skvarka elected as Class III directors with 20.7M and 23.5M votes for, respectively.
Ratification of Ernst & Young as auditor for FY2026 passed with 49.3M votes for (99.7% of votes cast).
Advisory say-on-pay proposal approved with 21.9M for vs 10.9M against, excluding broker non-votes.
Approximately 69.5% of outstanding shares (49.5M) were represented at the meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Zentalis Pharmaceuticals, Inc. shareholders approved Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-16 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-16

Exact text from the filing

Item 1 — Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes David Johnson 20,711,869 12,215,784 16,526,113 Jan Skvarka, Ph.D. 23,497,184 9,430,469 16,526,113

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Zentalis Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-16 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-16

Exact text from the filing

Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,949,844 10,930,673 47,136 16,526,113

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Zentalis Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-16 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-16

Exact text from the filing

Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 49,321,951 13,557 118,258 0

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-26-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.